Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 5:02 AM
Ignite Modification Date: 2025-12-25 @ 5:02 AM
NCT ID: NCT05471518
Eligibility Criteria: Inclusion Criteria: 1. Pre- (18-44 y) and post-menopausal (55-75 y) women 2. Individuals with CKD including stage 3-4 (eGFR 15-59 ml/min/1.73m2) determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation AND/OR urinary albumin-creatinine ratio (UACR) ≥ 30. 3. Controls must be healthy (free from hypertension, kidney disease, cardiovascular disease, diabetes, and other chronic disease as assessed by self-report, medical history, and screening labs). Premenopausal healthy women must have a regular menstrual cycle (25-35 d). Exclusion Criteria: 1. Perimenopausal (45-54 y) women 2. Pregnancy, lactation, or less than one year post-partum 3. Use of hormonal birth control methods, hormone replacement therapy, or a levonorgestrel intrauterine device (IUD) insertion for a duration less than 6 months 4. Advanced CKD requiring dialysis 5. History of kidney transplant 6. Use of immunosuppressant medications (unless taking a stable dosage for a quiescent disease in CKD group) 7. Antioxidant and/or omega-3 fatty acid use within the 2 weeks prior to testing 8. Current tobacco or nicotine use or history of use in the last 12 months 9. Marijuana use within 2 weeks prior to testing 10. Uncontrolled hypertension in CKD group (BP \>140/90 mmHg) 11. Atrial fibrillation 12. Active infection or antibiotic therapy 13. Hospitalization in the last month
Sex: FEMALE
Minimum Age: 18 Years
Maximum Age: 75 Years
Study: NCT05471518
Study Brief:
Protocol Section: NCT05471518